
The CHMP backed sintilimab plus chemotherapy in NSCLC; the FDA issued a complete response letter for the regimen in 2022.
Phase II data show Silevertinib boosts responses and brain control in treatment‑naive EGFR non‑classical NSCLC, with manageable rash/diarrhea.
Silevertinib is a brain-penetrant therapeutic option designed to target a wide range of non-classical EGFR mutations in non-small cell lung cancer. In its Phase 2 evaluation for first-line treatment, the drug demonstrated meaningful systemic tumor reduction and notable central nervous system activity for individuals presenting with brain metastases. The treatment carries a safety profile typical of its drug class, with side effects that remain manageable through supportive care interventions and strategic dose modifications.






